Comparison of Pivotal Medial Polyethylene Versus Ultra-congruent in Total Knee Arthroplasty
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Nov 4, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different types of materials used in total knee replacement surgery: medial pivot polyethylene and ultra-congruent polyethylene. The goal is to see which material helps patients feel like they have "forgotten" about their knee joint after the surgery, indicating a better quality of life and function.
To participate in this study, you need to be between 18 and 90 years old and have been approved for a primary knee replacement due to knee arthritis, known as gonarthrosis. You'll also need to be able to give your consent to join the study and have social security coverage. If you have certain conditions, like a recent infection in the knee or significant deformities, you won't be eligible. If you join the trial, you can expect to be part of a group that is trying to improve knee replacement outcomes for future patients. The study is currently looking for participants.
Gender
ALL
Eligibility criteria
- Inclusion criteria :
- • Subjects 18 to 90 years of age, eligible for a primary total knee replacement for gonarthrosis
- • Competent subjects able to give informed consent to participate in the research
- • Affiliation to the social security system
- Exclusion criteria :
- • Infection history of the knee to be replaced
- • Deformity greater than 15 degrees
- • Any surgical and/or anesthetic contraindication, or any condition deemed by the investigator to be incompatible with the research.
- • Any contraindication mentioned in the instructions for use of the medical device
- • Pregnant or breastfeeding women
- • Recent infection history of the surgical site
- • Adults who are subject to a legal protection measure or who are unable to express their constent (Article L1121-8 of the French Public Health Code) and subjects under judicial protection (article L. 1122-2 FPHC)
- • Subjects who refuse to participate
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Patients applied
Trial Officials
Stéphane DESCAMPS
Principal Investigator
University Hospital, Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported